Can Rising Amputation Rates Establish Xylazine Exposure in Individual Patients?
When an outcome increases as a drug supply changes, the timing can justify investigation. Establishing whether the change caused an individual outcome requires evidence at the patient level. A Philadelphia hospital study illustrates the difference.
What the records showed
Laurano and colleagues analyzed 20,595 acute-care visits by 12,047 patients with an opioid-related diagnosis code at four hospitals from 2018 through 2023. The study reported amputation in 0.81% in 2018 and 1.55% in 2023. In the adjusted comparison, the odds in 2022–2023 were 2.08 times the odds in 2018–2019, with a 95% confidence interval of 1.43 to 3.01. That estimate compares odds between periods.
What the calendar period represented
The researchers used year as a proxy for changes in the local supply. They did not confirm xylazine exposure or active substance use for each patient. The analysis considered factors including diabetes and leaving before treatment completion, but a calendar comparison may also capture other changes in patients, exposures, and care.
Applying the results to a specific case
The study documents a trend in the records reviewed. An opinion about one amputation would need to account for the patient’s exposure evidence, wound course, other potential causes and timing. The period in which treatment occurred cannot substitute for those facts.
Study
Laurano R, Pogorzelska-Maziarz M, Green TC, et al. Amputation trends among people who use drugs in the context of Philadelphia’s increasingly xylazine adulterated drug supply. Drug and Alcohol Dependence. 2025;275:112826. DOI 10.1016/j.drugalcdep.2025.112826.



